DexCom EBITDA 2010-2024 | DXCM

DexCom EBITDA for the quarter ending December 31, 2024 was $0.247B, a 8.43% decline year-over-year.

  • DexCom 2024 EBITDA was 0.818B, a 4.34% increase from 2023.
  • DexCom 2023 EBITDA was 0.784B, a 43.25% increase from 2022.
  • DexCom 2022 EBITDA was 0.547B, a 48.75% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Intuitive Surgical (ISRG)$171.9B
Thermo Fisher Scientific (TMO)$161.4B
Alcon (ALC)$45.6B
Edwards Lifesciences (EW)$42B
IDEXX Laboratories (IDXX)$33.3B
IQVIA Holdings (IQV)$25.4B
STERIS (STE)$21.8B
Mettler-Toledo (MTD)$20.9B
Waters (WAT)$19.1B
SONOVA HOLDING (SONVY)$17.3B
Fresenius Medical Care AG KGaA (FMS)$13.9B
Hologic (HOLX)$12.9B
Sysmex ADR (SSMXY)$11.8B
Penumbra (PEN)$10.7B
Globus Medical (GMED)$9.8B
Masimo (MASI)$8.2B
Teleflex (TFX)$6B
Glaukos (GKOS)$5.2B
Integer Holdings (ITGR)$4.1B
TransMedics (TMDX)$3B
PROCEPT BioRobotics (PRCT)$2.9B
Veracyte (VCYT)$2.4B
Nihon Kohden (NHNKY)$2.1B
LivaNova (LIVN)$1.9B
Elekta AB (EKTAY)$1.9B
Alphatec Holdings (ATEC)$1.5B
Integra LifeSciences Holdings (IART)$1.2B
Pulse Biosciences (PLSE)$1.2B
Tandem Diabetes Care (TNDM)$1.1B
Paragon 28 (FNA)$1.1B